Cancer Current Trials

Celldex has two clinical programs currently under clinical evaluation for the therapy of cancer.

• CDX-110 - Clinical Program for Malignant Glioblastoma (GBM)
  Our lead clinical development program, CDX-110, is an immunotherapy that targets the tumor specific molecule called EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy. While many different epithelial tumors express this antigen, GBM has a particularly dire prognosis and is our primary indication at this time. Additional tumors will be evaluated in collaboration with Pfizer, our partner on this program.
• CDX-1307 - Clinical Program in hCG-Beta expressing malignancies
  Our lead APC Targeting Technology™ product candidate, CDX-1307, is in Phase 1 development for the treatment of colorectal, pancreatic, bladder, ovarian and breast cancers. CDX-1307 targets the beta chain of human chorionic gonadotropin, known as hCG-β, an antigen often found in tumors of these, and other types of cancer. Two Phase 1 studies are evaluating the safety and biologic activity of either local or systemic dosing of CDX-1307, both alone and combined with immunomodulators.